SLNO Form 4: Director awarded 10,046 RSUs with staged vesting

Rhea-AI Filing Summary

Soleno Therapeutics (SLNO) disclosed a director equity award. On 10/13/2025, the reporting person was granted 10,046 restricted stock units (RSUs) at $0. Each RSU represents the right to receive one share of common stock.

Vesting: one-third on October 13, 2026 and on each one-year anniversary thereafter, subject to continued service. Beneficial ownership following the grant was 10,046 shares, held directly.

Insider Trade Summary

Net Buyer: 10,046 shares

Net Buy 1 txn

Insider Hahn Mark W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,046	$0.00	$0.00

Holdings After Transaction: Common Stock — 10,046 shares (Direct)

Footnotes (1)

1. F1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on October 13, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/14/2025 - 04:23 PM Learn about SEC filing dates

FAQ

What did Soleno Therapeutics (SLNO) disclose in this Form 4?

A director received 10,046 RSUs on 10/13/2025, each representing one share of common stock.

What is the vesting schedule for the 10,046 RSUs at SLNO?

One-third vests on October 13, 2026 and each one-year anniversary thereafter, contingent on continued service.

What was the price for the RSU grant reported by SLNO?

The RSUs were granted at $0 as shown in the filing.

What is the reporting person’s relationship to Soleno Therapeutics (SLNO)?

The reporting person is a Director of Soleno Therapeutics.

How many shares did the reporting person beneficially own after the transaction at SLNO?

10,046 shares, held directly, following the reported grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hahn Mark W

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/13/2025		A		10,046(1)	A	$0	10,046(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on October 13, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.